CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 150 enrolled
Drug / intervention
Stereotactic Body Radiation Therapy (SBRT) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02880319
NCT02880319Phase 2Active

Phase II Protocol Evaluating Stereotactic Body Radiation Therapy for Oligometastatic Disease of the Bone

Dana-Farber Cancer Institute·interventional·Posted Aug 26, 2016·Updated Sep 9, 2025

In Brief

A Phase 2 clinical trial evaluating Stereotactic Body Radiation Therapy (SBRT) and Stereotactic Linear Accelerator for Bone Cancer. Active but no longer recruiting, targeting 150 participants across 1 site.

Detailed Summary

This research study is studying a form of radiation therapy called stereotactic body radiation therapy or SBRT as a possible treatment for Cancer that has spread to the spine or other bone

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBone Cancer
CountriesUnited States
Collaborators--

Timeline

Phase 2Active
20172018201920202021202220232024202520262027
First PostedAug 26, 2016
Enrollment StartNov 29, 2016
Primary CompletionMay 1, 2022
Study CompletionMay 1, 2027
TodayJul 2, 2026
Enrollment to primary: 5.4 yearsPosted 9.8 years ago

Interventions

Stereotactic Body Radiation Therapy (SBRT)drug

Stereotactic Linear Acceleratordevice